May.04 -- Julie Gerberding, executive vice president and chief patient officer of Merck & Co. and former director of the U.S. Centers for Disease Control and Prevention, discusses the Covid-19 pandemic and how the Kenilworth, N.J.-based drugmaker is contributing to the fight against the virus. Merck said last month it has entered into non-exclusive voluntary licensing agreements for molnupiravir, an investigational oral antiviral agent for Covid, with five established Indian generics manufacturers. Gerberding speaks on "Bloomberg Daybreak: Australia."